After several years of legal sparring, Abbott Laboratories (ABT) and AbbVie (ABBV) will pay $25 million to settle allegations of paying kickbacks to doctors and illegally marketing the TriCor cholesterol pill.
The case began with a whistleblower lawsuit filed in 2009 by a former saleswoman for Abbott, which marketed the medicine at the time and later transferred the rights after spinning off AbbVie. The sales rep, Amy Bergman, alleged she was “trained, directed, incentivized, and encouraged” to promote TriCor for so-called off-label marketing and medically unnecessary uses.
About the Author Reprints
